Practical and operational considerations related to paediatric oral drug formulation: An industry survey. Download our resource today.
Quotient Sciences and Astrazeneca Co-Authored Scientific Publication evaluating the mass balance recovery and disposition of AZD4831 in humans. Download our publication here.
MK-X had demonstrated poor colonic absorption in dogs and conventional matrix-based controlled release formulations failed to achieve adequate trough concentrations in a human pharmacokinetic (PK) study to support once-daily dosing.
Download Quotient Sciences', 'Rapid Formulation Development & Clinical Testing of Gastro-Retentive Controlled Release Tech to Enable Once-Daily Dosing'.
Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers. Download our scientific poster titled, 'Clinical Pharmacokinetics and Pharmacodynamics of ME-401' from AACR 2016.
A randomized double-blind dose escalation study to evaluate the safety and dose-response of subcutaneous administration of coversin in healthy subjects.
Download a copy of our scientific poster from ASCPT 2016 titled, 'A randomized double-blind dose escalation study of coversin'.
When administered orally, peptide-based drugs are susceptible to degradation in the stomach due to exposure to low pH and proteolytic enzymes.
Download our poster from ADA 2017 titled, 'A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide'.
Absorption of oral peptide-based drug formulations is challenged by the fact that peptides are degraded in the stomach due to low pH and proteolytic enzymes, as well as by their limited permeability across the gastrointestinal epithelium.
Download our scientific poster entitled, 'Site of absorption of an oral formulation of semaglutide' from ADA 2017.
Maximizing the Potential of Amorphous Spray-Dried Dispersions to Enhance Clinical Bioavailability. Amorphous Dispersions (ADs) provide an effective approach to oral bioavailability improvement for poorly soluble compounds.
Download a copy of our poster from AAPS 2016 titled, 'A Rapid Formulation Development and Clinical Testing Program to evaluate the Pharmacokinetics of a novel enabled formulation of Abiraterone Acetate'.
Download a copy of our poster from AAPS 2016 titled, 'A Rapid Formulation Development and Clinical Testing Program to
evaluate the pharmacokinetics of a novel enabled formulation of Abiraterone acetate'.